ICU Medical, Inc.
ICUIHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. At a $4.17B market cap, ICU Medical, Inc. ranks as a mid-cap company within healthcare. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products.
Market Cap
$4.17B
Beta
0.86
P/E (TTM)
141.20
P/E (Fwd)
17.27
EPS (TTM)
$1.18
EPS (Fwd)
$9.65
ROE
1.4%
ROA
1.9%
Cash
$302.6M
Total Debt
$1.29B
Free CF
$163.6M
52W Change
34.9%
Annual Financials
Cash vs Debt
Where ICUI stands vs its 150-day and 200-day moving averages
As of the September 29, 2026 close, ICUI finished 12.44% above its 150-day moving average ($145.88) and 11.75% above its 200-day moving average ($146.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ICUI overbought or oversold?
At the September 29, 2026 close, ICUI's RSI(14) was 56.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $302.6M in cash, though total debt stands at $1.29B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $163.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 1.4% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.9% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.28B (2022) to $2.23B (2025).
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ICU Medical, Inc.'s trajectory.